JPS5922901A - ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 - Google Patents
ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤Info
- Publication number
- JPS5922901A JPS5922901A JP57132790A JP13279082A JPS5922901A JP S5922901 A JPS5922901 A JP S5922901A JP 57132790 A JP57132790 A JP 57132790A JP 13279082 A JP13279082 A JP 13279082A JP S5922901 A JPS5922901 A JP S5922901A
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- starch
- conjugate
- reaction
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002472 Starch Polymers 0.000 title claims abstract description 82
- 239000008107 starch Substances 0.000 title claims abstract description 82
- 239000003527 fibrinolytic agent Substances 0.000 title claims abstract description 8
- 229960000103 thrombolytic agent Drugs 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000002131 composite material Substances 0.000 title abstract 4
- 229960005356 urokinase Drugs 0.000 claims abstract description 89
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 86
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 85
- 235000019698 starch Nutrition 0.000 claims abstract description 55
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 abstract description 6
- 229910052751 metal Inorganic materials 0.000 abstract description 5
- 239000002184 metal Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 4
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 239000007800 oxidant agent Substances 0.000 abstract description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 2
- 239000007853 buffer solution Substances 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 150000001638 boron Chemical class 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000002537 thrombolytic effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000009739 binding Methods 0.000 description 8
- -1 cyanoborohydride Chemical compound 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000190020 Zelkova serrata Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- MYGMBVDLWDZOIL-UHFFFAOYSA-N methane;cyanide Chemical compound C.N#[C-] MYGMBVDLWDZOIL-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57132790A JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57132790A JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5922901A true JPS5922901A (ja) | 1984-02-06 |
| JPH036790B2 JPH036790B2 (enrdf_load_stackoverflow) | 1991-01-30 |
Family
ID=15089604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57132790A Granted JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5922901A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6460380A (en) * | 1987-08-31 | 1989-03-07 | Wako Pure Chem Ind Ltd | Stabilization of enzyme |
| JP2002528605A (ja) * | 1998-11-02 | 2002-09-03 | ネーデルランドセ・オルガニザテイエ・フール・テゲパスト−ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー | 炭水化物の酸化生成物および誘導体 |
-
1982
- 1982-07-28 JP JP57132790A patent/JPS5922901A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6460380A (en) * | 1987-08-31 | 1989-03-07 | Wako Pure Chem Ind Ltd | Stabilization of enzyme |
| JP2002528605A (ja) * | 1998-11-02 | 2002-09-03 | ネーデルランドセ・オルガニザテイエ・フール・テゲパスト−ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー | 炭水化物の酸化生成物および誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH036790B2 (enrdf_load_stackoverflow) | 1991-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015242970B2 (en) | Glycopolysialylation of non-blood coagulation proteins | |
| US4640835A (en) | Plasminogen activator derivatives | |
| JP3398150B2 (ja) | 新規接合体、その調製および使用ならびにその接合体を用いて調製された基体 | |
| DE69637179T2 (de) | Angiostatinfragmente und verfahren für deren verwendung | |
| JPH0525470B2 (enrdf_load_stackoverflow) | ||
| JPS63284134A (ja) | 抗腫瘍巨大分子白金化合物 | |
| US4446316A (en) | Dextran derivative of fibrinolysin | |
| EP1459738B1 (en) | Pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties | |
| JP2008263991A (ja) | 修飾されたアネキシン蛋白質および血栓症を防ぐための方法 | |
| CN102481345A (zh) | 精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途 | |
| JP2010515694A (ja) | アンギオスタチンあるいはその断片を含む複合体、その調製法および応用 | |
| JPS59172425A (ja) | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 | |
| JPS59500273A (ja) | 優れた効能を有するダウノルビシンの如き抗腫瘍剤、その製造方法および抗腫瘍剤の効能を高める方法 | |
| JPS5922901A (ja) | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 | |
| CA2314716C (en) | Modified polysaccharides exhibiting altered biological recognition | |
| JPH0222233A (ja) | スーパーオキシドディスムターゼ組成物 | |
| JPH0215193B2 (enrdf_load_stackoverflow) | ||
| JPH02231078A (ja) | ヒアルロン酸修飾スーパーオキシドジスムターゼ | |
| JPS6360938A (ja) | 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法 | |
| JPS6043116B2 (ja) | ウロキナ−ゼ誘導体 | |
| US20030236224A1 (en) | Modified polysaccharides exhibiting altered biological recognition | |
| JPS5920301A (ja) | ウロキナ−ゼ・デキストラン誘導体の製造法 | |
| AU2016362606A1 (en) | Factor VIII with extended half-life and reduced ligand-binding properties | |
| JPS5945881A (ja) | ウロキナ−ゼ・糖結合物及びその製造法 | |
| RU2556378C2 (ru) | Конъюгат гликопротеина, обладающего активностью эритропоэтина, с производными n-оксида поли-1,4-этиленпиперазина (варианты), фармацевтическая композиция и способ получения конъюгата |